Advertisement

Breast Cancer Research and Treatment

, Volume 127, Issue 2, pp 489–495 | Cite as

Germline mutations in BRCA1 and BRCA2 genes in ethnically diverse high risk families in Israel

  • Yael Laitman
  • Roni Tsipora Borsthein
  • Dominique Stoppa-Lyonnet
  • Efrat Dagan
  • Laurent Castera
  • Maud Goislard
  • Ruth Gershoni-Baruch
  • Hadassah Goldberg
  • Bella Kaufman
  • Noa Ben-Baruch
  • Jamal Zidan
  • Taiseer Maray
  • Lior Soussan-Gutman
  • Eitan Friedman
Epidemiology

Abstract

Three mutations in BRCA1 (185delAG, 5382InsC) and BRCA2 (6174delT) predominate among high risk breast ovarian cancer Ashkenazi Jewish families, with few “private” mutations described. Additionally, the spectrum of BRCA1 and BRCA2 germline mutations among high risk Jewish non Ashkenazi and non Jewish Israelis is undetermined. Genotyping by exon-specific sequencing or heteroduplex analysis using enhanced mismatch mutation analysis was applied to 250 high risk, predominantly cancer affected, unrelated Israeli women of Ashkenazi (n = 72), non Ashkenazi (n = 90), Moslem (n = 45), Christian Arabs (n = 21), Druze (n = 17), and non Jewish Caucasians (n = 5). All Jewish women were prescreened and did not harbor any of the predominant BRCA1 or BRCA2 Jewish mutations. Age at diagnosis of breast cancer (median ± SD) (n = 219) was 40.1 ± 11.7, 45.6 ± 10.7, 38.7 ± 9.2, 45.5 ± 11.4 ± and 40.7 ± 8.1 years for Ashkenazi, non Ashkenazi, Moslem, Christian, and Druze participants, respectively. For ovarian cancer (n = 19) the mean ages were 45.75 ± 8.2, 57.9 ± 10.1, 54 ± 8, 70 ± 0, and 72 ± 0 for these origins, respectively. Overall, 22 (8.8%) participants carried 19 clearly pathogenic mutations—10 BRCA1 and 9 BRCA2 (3 novel): 3 in Ashkenazim, 6 in 8 non-Ashkenazim, 6 in 7 Moslems, 2 in Druze, and 2 in non Jewish Caucasians. Only three mutations (c.1991del4, C61G, A1708E) were detected in 2 seemingly unrelated families of Moslem and non- Ashkenazi origins. There were no inactivating mutations among 55 Ashkenazi high risk breast cancer only families. In conclusion, there are no predominant recurring germline mutations in BRCA1 or BRCA2 genes among ethnically diverse Jewish and non Jewish high risk families in Israel.

Keywords

Germline mutations BRCA1BRCA2 High risk families Moslem Druze 

References

  1. 1.
    Petrucelli N, Daly MB, Feldman GL (2010) Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2. Genet Med 12(5):245–259PubMedCrossRefGoogle Scholar
  2. 2.
    Thorlacius S, Struewing JP, Hartge P, Olafsdottir GH, Sigvaldason H, Tryggvadottir L, Wacholder S, Tulinius H, Eyfjörd JE (1998) Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet 352(9137):1337–1339PubMedCrossRefGoogle Scholar
  3. 3.
    Górski B, Cybulski C, Huzarski T, Byrski T, Gronwald J, Jakubowska A, Stawicka M, Gozdecka-Grodecka S, Szwiec M, Urbański K, Mituś J, Marczyk E, Dziuba J, Wandzel P, Surdyka D, Haus O, Janiszewska H, Debniak T, Tołoczko-Grabarek A, Medrek K, Masojć B, Mierzejewski M, Kowalska E, Narod SA, Lubiński J (2005) Breast cancer predisposing alleles in Poland. Breast Cancer Res Treat 92(1):19–24PubMedCrossRefGoogle Scholar
  4. 4.
    Sokolenko AP, Mitiushkina NV, Buslov KG, Bit-Sava EM, Iyevleva AG, Chekmariova EV, ESh Kuligina, Ulibina YM, Rozanov ME, Suspitsin EN, Matsko DE, Chagunava OL, Trofimov DY, Devilee P, Cornelisse C, Togo AV, Semiglazov VF, Imyanitov EN (2006) High frequency of BRCA1 5382insC mutation in Russian breast cancer patients. Eur J Cancer 42(10):1380–1384PubMedCrossRefGoogle Scholar
  5. 5.
    Heimdal K, Maehle L, Apold J, Pedersen JC, Møller P (2003) The Norwegian founder mutations in BRCA1: high penetrance confirmed in an incident cancer series and differences observed in the risk of ovarian cancer. Eur J Cancer 39(15):2205–2213PubMedCrossRefGoogle Scholar
  6. 6.
    Abeliovich D, Kaduri L, Lerer I, Weinberg N, Amir G, Sagi M, Zlotogora J, Heching N, Peretz T (1997) The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet 60(3):505–514PubMedGoogle Scholar
  7. 7.
    Tobias DH, Eng C, McCurdy LD, Kalir T, Mandelli J, Dottino PR, Cohen CJ (2000) Founder BRCA 1 and 2 mutations among a consecutive series of Ashkenazi Jewish ovarian cancer patients. Gynecol Oncol 78(2):148–151PubMedCrossRefGoogle Scholar
  8. 8.
    Warner E, Foulkes W, Goodwin P, Meschino W, Blondal J, Paterson C, Ozcelik H, Goss P, Allingham-Hawkins D, Hamel N, Di Prospero L, Contiga V, Serruya C, Klein M, Moslehi R, Honeyford J, Liede A, Glendon G, Brunet JS, Narod S (1999) Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst 91(14):1241–1247PubMedCrossRefGoogle Scholar
  9. 9.
    Hartge P, Struewing JP, Wacholder S, Brody LC, Tucker MA (1999) The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. Am J Hum Genet 64(4):963–970PubMedCrossRefGoogle Scholar
  10. 10.
    Kauff ND, Perez-Segura P, Robson ME, Scheuer L, Siegel B, Schluger A, Rapaport B, Frank TS, Nafa K, Ellis NA, Parmigiani G, Offit K (2002) Incidence of non-founder BRCA1 and BRCA2 mutations in high risk Ashkenazi breast and ovarian cancer families. J Med Genet 39(8):611–614PubMedCrossRefGoogle Scholar
  11. 11.
    Palma MD, Domchek SM, Stopfer J, Erlichman J, Siegfried JD, Tigges-Cardwell J, Mason BA, Rebbeck TR, Nathanson KL (2008) The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high-risk breast cancer families. Cancer Res 68(17):7006–7014PubMedCrossRefGoogle Scholar
  12. 12.
    Shiri-Sverdlov R, Gershoni-Baruch R, Ichezkel-Hirsch G, Gotlieb WH, Bruchim Bar-Sade R, Chetrit A, Rizel S, Modan B, Friedman E (2001) The Tyr978X BRCA1 mutation in Non-Ashkenazi Jews: occurrence in high-risk families, general population and unselected ovarian cancer patients. Community Genet 4(1):50–55PubMedCrossRefGoogle Scholar
  13. 13.
    Lerer I, Wang T, Peretz T, Sagi M, Kaduri L, Orr-Urtreger A, Stadler J, Gutman H, Abeliovich D (1998) The 8765delAG mutation in BRCA2 is common among Jews of Yemenite extraction. Am J Hum Genet 63(1):272–274PubMedCrossRefGoogle Scholar
  14. 14.
    Tarabeia J, Baron-Epel O, Barchana M, Liphshitz I, Ifrah A, Fishler Y, Green MS (2007) A comparison of trends in incidence and mortality rates of breast cancer, incidence to mortality ratio and stage at diagnosis between Arab and Jewish women in Israel, 1979–2002. Eur J Cancer Prev 16(1):36–42PubMedCrossRefGoogle Scholar
  15. 15.
    Nissan A, Spira RM, Hamburger T, Badriyyah M, Prus D, Cohen T, Hubert A, Freund HR, Peretz T (2004) Clinical profile of breast cancer in Arab and Jewish women in the Jerusalem area. Am J Surg 188:62–67PubMedCrossRefGoogle Scholar
  16. 16.
    Ibrahim EM, al-Mulhim FA, al-Amri A, al-Muhanna FA, Ezzat AA, Stuart RK, Ajarim D (1998) Breast cancer in the eastern province of Saudi Arabia. Med Oncol 15:241–247PubMedCrossRefGoogle Scholar
  17. 17.
    El-Harith el HA, Abdel-Hadi MS, Steinmann D, Dork T (2000) BRCA1 and BRCA2 mutations in breast cancer patients from Saudi Arabia. Saudi Med J 23:700–704Google Scholar
  18. 18.
    Kadouri L, Bercovich D, Elimelech A, Lerer I, Sagi M, Glusman G, Shochat C, Korem S, Hamburger T, Nissan A, Abu-Halaf N, Badrriyah M, Abeliovich D, Peretz T (2007) A novel BRCA-1 mutation in Arab kindred from east Jerusalem with breast and ovarian cancer. BMC Cancer 7:14Google Scholar
  19. 19.
    Atoum MF, Al-Kayed SA (2004) Mutation analysis of the breast cancer gene BRCA1 among breast cancer Jordanian females. Saudi Med J 25(1):60–63PubMedGoogle Scholar
  20. 20.
    Troudi W, Uhrhammer N, Sibille C, Dahan C, Mahfoudh W, Bouchlaka Souissi C, Jalabert T, Chouchane L, Bignon YJ, Ben Ayed F, Ben Ammar Elgaaied A (2007) Contribution of the BRCA1 and BRCA2 mutations to breast cancer in Tunisia. J Hum Genet 52(11):915–920PubMedCrossRefGoogle Scholar
  21. 21.
    Eachkoti R, Hussain I, Afroze D, Aejazaziz S, Jan M, Shah ZA, Das BC, Siddiqi MA (2007) BRCA1 and TP53 mutation spectrum of breast carcinoma in an ethnic population of Kashmir, an emerging high-risk area. Cancer Lett 248(2):308–320PubMedCrossRefGoogle Scholar
  22. 22.
    Troudi W, Uhrhammer N, Romdhane KB, Sibille C, Amor MB, Khodjet El Khil H, Jalabert T, Mahfoudh W, Chouchane L, Ayed FB, Bignon YJ, Elgaaied AB (2008) Complete mutation screening and haplotype characterization of BRCA1 gene in Tunisian patients with familial breast cancer. Cancer Biomark 4(1):11–18PubMedGoogle Scholar
  23. 23.
    Uhrhammer N, Abdelouahab A, Lafarge L, Feillel V, Ben Dib A, Bignon YJ (2008) BRCA1 mutations in Algerian breast cancer patients: high frequency in young, sporadic cases. Int J Med Sci 5(4):197–202PubMedGoogle Scholar
  24. 24.
    Moattar T, Kausar T, Aban M, Khan S, Pervez S (2006) Medullary carcinoma of breast with a novel germline mutation 1123T>G in exon 11 of BRCA1. J Coll Physicians Surg Pak 16(9):606–607PubMedGoogle Scholar
  25. 25.
    Liede A, Malik IA, Aziz Z, Rios Pd Pde L, Kwan E, Narod SA (2002) Contribution of BRCA1 and BRCA2 mutations to breast and ovarian cancer in Pakistan. Am J Hum Genet 71(3):595–606PubMedCrossRefGoogle Scholar
  26. 26.
    Rashid MU, Zaidi A, Torres D, Sultan F, Benner A, Naqvi B, Shakoori AR, Seidel-Renkert A, Farooq H, Narod S, Amin A, Hamann U (2006) Prevalence of BRCA1 and BRCA2 mutations in Pakistani breast and ovarian cancer patients. Int J Cancer 119(12):2832–2839PubMedCrossRefGoogle Scholar
  27. 27.
    Nissim D (2003) The Druze in the Middle East: their faith, leadership, identity and status. Sussex Academic Press, Brighton, pp 227. ISBN: 978-1903900369Google Scholar
  28. 28.
    Lynch HT, Watson P, Tinley S, Snyder C, Durham C, Lynch J, Kirnarsky Y, Serova O, Lenoir G, Lerman C, Narod SA (1999) An update on DNA-based BRCA1/BRCA2 genetic counseling in hereditary breast cancer. Cancer Genet Cytogenet 109:91–98PubMedCrossRefGoogle Scholar
  29. 29.
    Shiri-Sverdlov R, Oefner P, Green L, Baruch RG, Wagner T, Kruglikova A, Haitchick S, Hofstra RM, Papa MZ, Mulder I, Rizel S, Bar Sade RB, Dagan E, Abdeen Z, Goldman B, Friedman E (2000) Mutational analyses of BRCA1 and BRCA2 in Ashkenazi and non-Ashkenazi Jewish women with familial breast and ovarian cancer. Hum Mutat 16(6):491–501PubMedCrossRefGoogle Scholar
  30. 30.
    Soegaard M, Kjaer SK, Cox M, Wozniak E, Høgdall E, Høgdall C, Blaakaer J, Jacobs IJ, Gayther SA, Ramus SJ (2008) BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark. Clin Cancer Res 14(12):3761–3767PubMedCrossRefGoogle Scholar
  31. 31.
    Houdayer C, Moncoutier V, Champ J, Weber J, Viovy JL, Stoppa-Lyonnet D (2010) Enhanced mismatch mutation analysis: simultaneous detection of point mutations and large scale rearrangements by capillary electrophoresis, application to BRCA1 and BRCA2. Methods Mol Biol 653:147–180PubMedCrossRefGoogle Scholar
  32. 32.
    Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE, Lingenfelter B, Gumpper KL, Scholl T, Tavtigian SV, Pruss DR, Critchfield GC (2002) Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 20(6):1480–1490PubMedCrossRefGoogle Scholar
  33. 33.
    Denic S, Al-Gazali L (2002) Breast cancer, consanguinity, and lethal tumor genes: simulation of BRCA1/2 prevalence over 40 generations. Int J Mol Med 10(6):713–719PubMedGoogle Scholar
  34. 34.
    Moncoutier V, Castera L, Tirapo C, Michaux D, Remon MA, Laugé A, Rouleau E, de Pauw A, Buecher B, Gauthier-Villars M, Viovy JL, Stoppa-Lyonnet D, Houdayer C (2010) EMMA, a cost- and time-effective diagnostic method for simultaneous detection of point mutations and large-scale genomic rearrangements: application to BRCA1 and BRCA2 in 1,525 patients. Hum Mutat (submitted)Google Scholar
  35. 35.
    Distelman-Menachem T, Shapira T, Laitman Y, Kaufman B, Barak F, Tavtigian S, Friedman E (2009) Analysis of BRCA1/BRCA2 genes’ contribution to breast cancer susceptibility in high risk Jewish Ashkenazi women. Fam Cancer 8(2):127–133PubMedCrossRefGoogle Scholar
  36. 36.
    Kaufman B, Laitman Y, Carvalho MA, Edelman L, Menachem TD, Zidan J, Monteiro AN, Friedman E (2006) The P1812A and P25T BRCA1 and the 5164del4 BRCA2 mutations: occurrence in high-risk non-Ashkenazi Jews. Genet Test 10(3):200–207PubMedCrossRefGoogle Scholar
  37. 37.
    Tavtigian SV, Deffenbaugh AM, Yin L, Judkins T, Scholl T, Samollow PB, de Silva D, Zharkikh A, Thomas A (2006) Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral. J Med Genet 43:295–305PubMedCrossRefGoogle Scholar
  38. 38.
    Katagiri T, Kasumi F, Yoshimoto M, Nomizu T, Asaishi K, Abe R, Tsuchiya A, Sugano M, Takai S, Yoneda M, Fukutomi T, Nanba K, Makita M, Okazaki H, Hirata K, Okazaki M, Furutsuma Y, Morishita Y, Iino Y, Karino T, Ayabe H, Hara S, Kajiwara T, Houga S, Shimizu T, Toda M, Ymazaki Y, Uchida T, Kunimoto K, Sonoo H, Kurebayashi J-I, Shimtsuma K, Nakamura Y, Miki Y (1998) High proportion of missense mutations of the BRCA1 and BRCA2 genes in Japanese breast cancer families. J Hum Genet 43(1):42–48PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2010

Authors and Affiliations

  • Yael Laitman
    • 1
  • Roni Tsipora Borsthein
    • 2
  • Dominique Stoppa-Lyonnet
    • 3
    • 4
    • 5
  • Efrat Dagan
    • 2
  • Laurent Castera
    • 3
  • Maud Goislard
    • 3
  • Ruth Gershoni-Baruch
    • 2
  • Hadassah Goldberg
    • 6
  • Bella Kaufman
    • 7
    • 12
  • Noa Ben-Baruch
    • 8
  • Jamal Zidan
    • 9
  • Taiseer Maray
    • 10
  • Lior Soussan-Gutman
    • 11
  • Eitan Friedman
    • 1
    • 12
  1. 1.The Susanne Levy Gertner Oncogenetics Unit, The Danek Gertner Institute of Human GeneticsChaim Sheba Medical CenterTel-HashomerIsrael
  2. 2.The Genetics Institute, Rambam Medical CenterHaifaIsrael
  3. 3.Département de BiologieInstitut Curie, HôpitalParisFrance
  4. 4.INSERM U830ParisFrance
  5. 5.Université Paris DescartesParisFrance
  6. 6.Oncology Institute, Rambam Medical CenterHaifaIsrael
  7. 7.The Oncology InstituteSheba Medical CenterHaifaIsrael
  8. 8.The Oncology Institute, Kaplan Medical CenterRehovotIsrael
  9. 9.The Oncology Institute, Ziv Medical CenterSafedIsrael
  10. 10.Golan for Development of the Arab Villages (GfD)Majdal ShamsIsrael
  11. 11.Oncotest TevaNetanyaIsrael
  12. 12.The Sackler School of MedicineTel-Aviv UniversityTel-AvivIsrael

Personalised recommendations